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of Cytochrome c Oxidase 2; shRNA, short hairpin RNA; siRNA, small interfering RNA; 
TIGAR, tp53 inducer and regulator of glycolysis, wt, wildtype. 
Abstract 
p53 has an important role in the processing of starvation signals. p53-dependent molecular 
mediators of the Warburg effect reduce glucose consumption and promote mitochondrial 
function. We therefore hypothesized that the retention of wild-type p53 characteristic of 
primary glioblastomas limits metabolic demands induced by deregulated signal transduction 
in the presence of hypoxia and nutrient depletion. Here we report that shRNA-mediated gene 
suppression of wild-type p53 or ectopic expression of mutant temperature-sensitive dominant-
negative p53V135A increased glucose consumption and lactate production, decreased oxygen 
consumption and enhanced hypoxia-induced cell death in p53 wild-type human glioblastoma 
cells. Similarly, genetic knock-out of p53 in HCT116 colon carcinoma cells resulted in 
reduced respiration and hypersensitivity towards hypoxia-induced cell death. Further, wild-
type p53 gene silencing reduced the expression of Synthesis of Cytochrome c Oxidase 2 
(SCO2), an effector necessary for respiratory chain function. A SCO2 transgene reverted the 
metabolic phenotype and restored resistance towards hypoxia in p53-depleted and in p53 
mutant glioma cells in a rotenone-sensitive fashion, demonstrating that this effect was 
dependent on intact oxidative phosphorylation. Supplementation with methyl-pyruvate, a 
mitochondrial substrate, rescued p53 wild-type but not p53 mutant cells from hypoxic cell 
death, demonstrating a p53-mediated selective aptitude to metabolize mitochondrial 
substrates. Further, SCO2 gene silencing in p53 wild-type glioma cells sensitized these cells 
towards hypoxia. Finally, lentiviral gene suppression of SCO2 significantly enhanced tumor 
necrosis in a subcutaneous HCT 116 xenograft tumor model, compatible with impaired 
energy metabolism in these cells. These findings demonstrate that glioma and colon cancer 
cells with p53 wild-type status can skew the Warburg effect and thereby reduce their 
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vulnerability towards tumor hypoxia in a SCO2-dependent fashion. Targeting SCO2 may 
therefore represent a valuable strategy to enhance sensitivity towards hypoxia and may 
complement strategies targeting glucose metabolism. 
 
Introduction 
Alteration of metabolism in tumor cells is increasingly recognized as a core component of the 
neoplastic phenotype that complements the classical hallmarks of cancer (Gottlieb, 2009; 
Hanahan and Weinberg, 2000). Otto Warburg in the early 1920s defined the phenomenon of 
aerobic glycolysis (Warburg, 1956a; Warburg, 1956b) characteristic of cancer cells 
preferentially utilizing the glycolytic pathway in the presence of oxygen, although less ATP 
per mole glucose is produced by glycolysis than by mitochondrial respiration. It has become 
evident, however, that increased glycolysis can be advantageous for tumors cells in many 
ways (DeBerardinis et al., 2008; Gatenby and Gillies, 2004; Kondoh et al., 2005; Moreno-
Sanchez et al., 2007). First, as long as sufficient glucose is available, energy demand can be 
satisfied by enhanced glycolytic activity, because the glycolytic flux involves fewer 
biochemical reactions than cellular respiration (Curi et al., 1988; Gatenby and Gillies, 2004; 
Guppy et al., 1993). Additionally, glycolysis provides cells with intermediate products needed 
for biosynthetic pathways including riboses for nucleotide setup and glycerate or citrate for 
lipid synthesis. Furthermore, the pentose phosphate pathway generates NADPH, acting as 
energy source and reducing agent for protection against reactive oxygen species (ROS). 
Several aspects of the molecular mechanisms underlying the glycolytic phenotype have 
recently been elucidated. Signaling downstream of receptor tyrosine kinases influences 
glucose metabolism. In particular, the phosphatidylinositol-3 kinase (PI3K)/protein kinase B 
(PKB)/Akt pathway that is activated in the vast majority of primary glioblastomas (Choe et 
al., 2003) increases glycolytic activity by upregulation of glucose transporter 1 (GLUT1) 
(Barnes et al., 2002) and phosphorylation of hexokinase-II (Miyamoto et al., 2008). 
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Another event important for the development of cancer is the inactivation of the tumor 
suppressor p53 (Vogelstein et al., 2000). Depending on the cellular conditions, p53 
suppresses tumorigenesis by multiple mechanisms, including cell cycle regulation, initiation 
of DNA repair, induction of apoptosis, activation of autophagy or protection from autophagy-
induced cell death and regulation of ROS production. Recently, however, p53 has been 
demonstrated to act also as a potent metabolic regulator. The p53-dependent metabolic 
response is driven by the starvation-sensitive AMP-activated protein kinase (AMPK) pathway 
(Jones et al., 2005). At least two effectors downstream of p53 have been identified. First, p53 
maintains mitochondrial respiration by inducing Synthesis of Cytochrome c Oxidase 2 (SCO2) 
(Matoba et al., 2006). SCO2 is essential for the proper assembly of cytochrome c oxidase 
(COX) which catalyzes the transfer of reducing equivalents from cytochrome c to molecular 
oxygen in the inner mitochondrial membrane. Loss of p53 or SCO2 results in a shift of 
metabolism towards glycolysis (Corcoran et al., 2006; Ma et al., 2007; Matoba et al., 2006). 
Additionally, p53 may suppress glycolysis and increase the activity of the pentose phosphate 
shunt via induction of tp53 inducer and regulator of glycolysis (TIGAR) (Bensaad et al., 
2006).  
Glioblastomas are amongst the most hypoxic human tumors, and primary glioblastomas, in 
particular, feature extensive necrosis. It is intriguing that almost all these tumors retain wild-
type p53 status in contrast to secondary glioblastomas arising from low-grade gliomas, in 
which mutation of p53 is frequent (Tohma et al., 1998; Watanabe et al., 1996). We therefore 
hypothesized that wild-type p53 in glioma cells limits metabolic demands induced by 
deregulated signal transduction processes in the presence of hypoxia and nutrient depletion 
and thereby enhances viability under the adverse conditions of the glioblastoma 
microenvironment.  
We here report that antagonism of p53 enhances the glycolytic phenotype and promotes 
hypoxia-induced cell death in a SCO2 dependent manner. SCO2 gene silencing mimicks the 
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effects of p53 suppression in vitro, while overexpression of SCO2 in cells with inactivated 
p53 confers the phenotype of p53 wild-type cells. 
 
Results 
Antagonizing p53 enhances hypoxia-induced cell death. 
To analyze the importance of p53 for the ability of glioma cells to survive hypoxic stress, 
three models of p53 inactivation were used. (i) LNT-229 glioma cells stably transfected with a 
short-hairpin RNA targeting p53 (p53sh), (ii) LNT-229 cells in which the p53 transactivation 
activity was inhibited by stable expression of the temperature-sensitive dominant-negative 
p53V135A mutant (Naumann et al., 1998) and iii) HCT116 human colon carcinoma cells 
carrying a targeted deletion of p53 achieved by homologous recombination (p53-/-) and 
appropriate control cells (Bunz et al., 1998; Ryan et al., 1993). In a first step, we analyzed the 
expression of p53 in tumor cells exposed to limited glucose availability (2 mM) and different 
oxygen concentrations (21%, 1% or 0.1% O2) (Fig. 1A). Hypoxia had no consistent effect on 
p53 protein levels. p53 protein levels in LNT-229 cells stably transfected with the p53sh 
sequence (LNT-229 p53sh cells) were efficiently reduced under all conditions. In LNT-229 
p53ts cells, the murine transgenic p53 was detectable in addition to the endogenous human 
p53. Again, hypoxia had no effect on endogenous (p53sc263-antibody) or on transgenic 
(p53Ab4-antibody) p53 protein levels. No p53 was detectable in HCT116 p53-/- cells. Since 
conflicting results concerning transcriptional activity of p53 under hypoxia exist (Liu et al., 
2007; Zhao et al., 2009), p53 transactivation activity under the experimental conditions was 
analyzed by luciferase assay. The p53-transactivation capacity was significantly reduced in 
p53-depleted cells (LNT-229 p53sh, LNT-229 p53ts and HCT116 p53-/-) at all experimental 
conditions (Fig. 1B). Furthermore, hypoxia per se did not significantly alter the p53 
transactivation activity. These results demonstrate that the expression of p53 and its 
transactivation activity are retained under starving conditions of hypoxia and glucose 
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deprivation. To test whether suppression of p53 modulates the sensitivity towards hypoxia-
induced cell death, LNT-229 puro/p53sh, LNT-229 hygro/p53ts and HCT116 p53+/+/p53-/- 
cells were exposed to glucose restriction (2 mM) and different oxygen concentrations (21%, 
1% or 0.1% O2) for 24 h, and cell death was assessed by propidium iodide (PI) staining. In all 
three paradigms the inactivation of p53 sensitized the cells towards hypoxia-induced cell 
death (Fig. 1C), an effect that was most prominent at moderate hypoxia. 
 
p53 is a regulator of glucose consumption in tumor cells. 
Since p53 plays a regulatory role in glucose metabolism during stress situations (Bensaad et 
al., 2006; Corcoran et al., 2006; Kondoh et al., 2005; Matoba et al., 2006), we hypothesized 
that suppression of wild-type p53 resulted in a higher nutrient demand under starvation 
conditions. This would accelerate nutrient depletion and promote earlier cell death. We 
compared glucose consumption and lactate production in LNT-229 puro/p53sh or HCT 
p53+/+/p53-/- cells in normoxia (21% O2) and hypoxia ((1% or 0,1% O2). p53-depleted cells 
showed an increased glucose consumption and lactate production under all conditions tested 
independent of oxygen supply (Fig. 2 A-D). Similar results were obtained with LNT-229 
hygro/p53ts cells (data not shown). Therefore, p53 deletion leads to an increased glucose 
consumption and consequently to an accelerated glucose depletion.  
 
Inhibiting p53 function represses cellular respiration. 
Recent work has elucidated that p53 enhances cellular respiration through transcriptional 
upregulation of SCO2, which is essential for the assembly of COX and thus maintains 
oxidative phosphorylation (Matoba et al., 2006). As p53-antagonized cells were more 
sensitive towards hypoxia, we hypothesized that this was elicited by regulation of SCO2. We 
therefore determined SCO2 expression by qRT-PCR analysis in these cell lines. Antagonizing 
p53 repressed SCO2 in glioma and colon carcinoma cells (Fig. 3A). To assess the functional 
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consequences of p53 deletion on cellular respiration, oxygen consumption was directly 
measured in p53-suppressed and control cell lines. As shown in Fig. 3B, loss of p53 wild-type 
activity led to a considerable reduction in oxygen consumption, confirming a regulatory 
function of p53 for cellular respiratory activity.  
 
SCO2 is a p53 effector that maintains respiration and reduces sensitivity towards 
hypoxic stress 
To characterize the role of SCO2 as an effector of p53, an SCO2 expression vector was 
transfected into LNT-229, LNT-229 p53sh or T98G (p53 mutant) cells. Additionally, 
expression of SCO2 was transiently suppressed by siRNA in parental LNT-229 cells (Fig. 
4A). Overexpression of SCO2 enhanced oxygen consumption in parental cells and rescued the 
suppression of respiration observed in p53sh cells, while gene suppression of SCO2 repressed 
respiration (Fig. 4B). To test whether restoration of SCO2 would also reconstitute resistance 
of p53-depleted cells towards hypoxia-induced cell death, p53sh cells transfected with SCO2 
or control vector were incubated at 21%, 1% or 0.1% O2 and cell death was assessed 
thereafter. Under moderately hypoxic conditions (1% O2), ectopic expression of SCO2 
protected wild-type LNT-229 cells from hypoxia-induced cell death and reverted the 
hypersensitivity of p53-depleted cells (Fig. 4C). Under profoundly hypoxic conditions (0.1% 
O2), however, the SCO2 transgene did not convey protection from hypoxia. Similarly, gene 
suppression of SCO2 enhanced the sensitivity of LNT-229 cells towards cell death only at 
moderate hypoxia, indicating that concentrations of oxygen sufficient for electron transfer 
within the mitochondrial respiratory chain are a prerequisite for the hypoxia-protective effects 
of SCO2 (Fig. 4C). Similar results were obtained with LN-18 (mutant p53) and LNT-229 
hygro/p53ts cells (data not shown).  
 
A functional respiratory chain is required for the SCO2-mediated protection 
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To determine whether the effect of SCO2 on hypoxia-induced cell death depends on its 
function related to the mitochondrial respiratory chain, SCO2-transfected LNT-229 p53sh 
cells were exposed to moderate hypoxia (1% O2) in the presence or absence of rotenone, an 
inhibitor of complex I of the respiratory chain. Rotenone profoundly repressed oxygen 
consumption in LNT-229 p53sh cells transfected with either control vector or SCO2 (Fig. 
5A). Hypoxia-induced cell death was unaffected by rotenone in LNT-229 p53sh cells 
transfected with control vector. The repression of cell death observed in SCO2-transfected 
cells was partly reverted by rotenone (Fig. 5B), indicating the requirement of a functional 
respiratory chain for SCO2´s function. Similar results were obtained in LNT-229 p53ts cells 
and in parental cells (data not shown). Supplementation of glucose rescued glioma cells 
irrespective of p53 status from hypoxic cell death suggesting that energy depletion is causal 
for the loss of cellular viability (Fig. 5 C). In contrast, methyl-pyruvate, a mitochondrial 
substrate, suppressed hypoxia-induced cell death only in p53 wild-type cells (Fig. 5 D). 
Cellular ATP concentrations in p53-depleted cells were decreased in hypoxia compared to 
p53 wild-type or SCO2 restored cells (Suppl. Fig. 1). However, no SCO2-dependent changes 
in the phosphorylation level of the energy-sensing kinase p-AMPKα or of its downstream 
targets actetyl coA carboxylase (ACC) or 4-EBP1 occurred (Suppl. Fig. 2). As SCO2 still had 
protective effects even in the presence of the complex I inhibitor rotenone, additional 
mechanisms independent of SCO2’s function in oxidative phosphorylation might exist. 
Because SCO2 has recently been shown to suppress ROS levels (Sung, 2010), we investigated 
whether ROS levels would be modulated by SCO2 under starvation conditions, too. Indeed, 
intracellular ROS concentrations were reduced by ectopic expression of SCO2 (Suppl. Fig. 3), 
supporting a role for SCO2 in decreasing ROS levels. 
 
Suppression of SCO2 does not impact on clonogenicity in vitro 
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To analyze if p53 or SCO2 modulate clonogenicity of colon cancer cells in vitro under 
physiological conditions (3% O2 and 5.5 mM glucose), anchorage independent growth was 
assessed by soft agar colony formation assays. To study in detail the role of SCO2, HCT116 
p53+/+ cells were stably transfected with a short-hairpin RNA targeting SCO2 (SCO2 sh) via a 
lentiviral system, resulting in about 75% knock-down in RT-PCR analysis (data not shown).  
Knock-out of p53 significantly impaired the ability of anchorage independent growth, 
whereas no such effect was observable in the SCO2-suppressed cells (Fig. 6). These results 
indicate that SCO2 does not impair clonogenic capacity per se in the presence of sufficient 
nutrients. 
 
Depletion of SCO2 promotes necrosis formation. 
As our in vitro models might not appropriately reflect the metabolic environment of tumor 
cells in vivo, we further analyzed the growth of  HCT116 p53+/+, p53-/-, p53+/+ scrambled sh 
and -SCO2 sh cells in a xenograft nude mouse model. No significant difference of the tumor 
growth doubling times could be observed between p53+/+ (4.55 ± 0.66 d) and p53-/- (4.26 ± 
0.99 d) tumors (Fig. 7A), but there was a tendency to produce larger tumors in HCT p53-/- 
cells at the end of the experiment (volumes at day 25 of HCT p53+/+ vs. HCT p53 -/- tumors: 
1321 ± 642 mm3 vs. 1718 ± 833 mm3, mean ± SD, p>0.05) in accordance with previous 
reports using similar cell numbers (Bhonde et al., 2006; Buzzai et al., 2007; Yoon et al., 
2009). Similarly, SCO2-suppressed tumors did not have significant altered doubling times 
compared to control tumors (6.3 ± 1.52 d vs. 5.3 ± 0.5 d), but the tumor volumes at the end of 
the experiment were slightly larger in SCO2-depleted tumors (volumes at day 31 of scr sh vs. 
SCO2 sh tumors: 1293 ± 350 mm3 vs. 1815 ± 641 mm3, mean ± SD, p<0.05, Fig. 7B). 
Because faster glucose depletion of SCO2-suppressed tumor cells in vitro (Fig. 2 and data not 
shown) might be expected to result in altered necrosis formation in vivo, the extent of necrosis 
in comparison to the total tumor area was determined. Whereas in control tumors, necrosis 
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had a patchy distribution pattern with islets of viable tumors within necrotic areas, SCO2-
suppressed tumors indeed revealed extensive central necrosis without viable tumors cells. 
Further, when the proportion of necrosis compared to the total tumor area was quantitatively 
analyzed, SCO2-suppressed tumors were characterized by significantly more necrosis 
compared to control tumors (Fig. 7C). 
 
Discussion 
p53 has recently been demonstrated to possess important functions in the control of cellular 
metabolism that may govern adaptive responses of tumor cells to their microenvironment. 
First, by mediating AMP kinase-induced growth arrest, p53 indirectly limits glucose 
consumption under starvation conditions (Jones et al., 2005). Second, the p53 target TIGAR 
inhibits glycolysis and increases metabolism in the pentose phosphate shunt (Bensaad et al., 
2006). Third, SCO2 has been shown to be a p53 target gene (Matoba et al., 2006) important 
for the assembly of the COX subunit within the inner mitochondrial membrane, thereby 
promoting cellular respiration (Leary et al., 2004; Leary et al., 2009). In summary, p53 serves 
as a key metabolic regulator limiting glucose consumption and increasing energy efficacy.  
In primary glioblastoma, despite its cell cycle-regulating and proapoptotic functions, p53 is 
retained in its wild-type state in almost all cases (Fults et al., 1992; Ohgaki and Kleihues, 
2007; Van Meir et al., 1994). In contrast, the receptor tyrosine kinase pathway is typically 
activated in these tumors leading to increased cellular metabolic demand and glucose 
consumption. Therefore, we hypothesized that the retention of wild-type p53 serves to adjust 
glucose metabolism in order to enable survival under the starvation conditions characteristic 
of the tumor microenvironment. 
We here report that, indeed, under hypoxia, inactivation of p53 increased glucose 
consumption and cell death. Expression of SCO2 was downregulated and oxygen 
consumption was suppressed by antagonism of p53 (Fig. 3) consistent with the observation 
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that SCO2 is regulated by p53 (Matoba et al., 2006). Transfection of SCO2 into p53 deficient 
cells reestablished the metabolic phenotype of p53 wild-type cells enabling cellular 
respiration and enhancing cellular survival (Fig. 4). Most likely, this is due to the better 
efficiency of mitochondrial respiration compared to glycolysis, with 36 mol of ATP generated 
by oxidative phosphorylation versus 2 mol generated in the glycolytic pathway. Excess 
glucose rescued hypoxia-induced cell death in glycolytic (p53 mutant) as well as oxidative 
(p53 wild-type or SCO2 transfected) cells (Fig. 5 C), supporting the assumption that energy 
depletion is causal for the loss of viability under hypoxia and that glucose can be metabolized 
irrespective of p53 status under these conditions. Supplementation with methyl-pyruvate 
rescued survival only in p53 wild-type cells, but not in p53 mutant cells (Fig. 5 D). This is 
indicative of a functional p53-dependent respiration and of a selective aptitude of p53 wild-
type cells compared to p53 mutant cells to metabolize mitochondrial substrates. p53 wild-type 
and SCO2 restored cells indeed maintained higher ATP levels under stress conditions than 
p53 mutant cells (Suppl. Fig. 1). However, although an increase in the phosphorylation level 
of the energy-sensing kinase AMPKα and subsequent modulation of its downstream targets 
acetyl coA carboxylase (ACC) or 4-EBP1 were detectable under hypoxic conditions, these 
adaptive responses were independent of the SCO2 expression (suppl. Fig. 2). Therefore, 
during hypoxia and glucose depletion, AMPK is activated irrespective of SCO2 status. We 
hypothesize that AMPK then triggers a starvation response that is more efficient in p53 wild-
type or SCO2 expressing cells because these are able to utilize energy-effective oxidative 
phosphorylation while p53 mutant or SCO2 deficient cells deplete their glucose stores more 
rapidly (see also Fig. 2). The ensuing profound ATP depletion resulting in cell demise is 
possibly too rapid to regulate, in turn, phospho-AMPK to higher levels in p53 mutant / SCO2 
deficient cells. 
Since SCO2 expression did not decrease cell death under profound hypoxia, SCO2 seems to 
specifically act as a hypoxia-protective protein in the presence of at least traces of oxygen. 
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Furthermore, the assumption that SCO2-mediated protection from hypoxia-induced cell death 
is related to its function at the mitochondrial respiratory chain and requires an intact oxidative 
phosphorylation is supported by the observation that the protective effect of SCO2 is 
attenuated by inhibition of oxidative phosphorylation with the complex I inhibitor rotenone 
(Fig. 5). Since the protective effect of SCO2 under hypoxia was only partially reverted by 
inhibition of the respiratory chain, we wondered if SCO2 might protect cells from stress 
conditions by additional mechanisms. As shown in Suppl. Fig. 3, SCO2 suppressed 
intracellular ROS concentrations in LNT-229 and T98G cells both at normoxia and hypoxia. 
Our results are in agreement with findings in colon carcinoma cells and fibroblasts (Sung, 
2010) and suggest that the suppression of ROS could be an additional cytoprotective 
mechanism of SCO2. How SCO2 suppresses ROS levels in glioma cells is unclear but might 
involve reduced intracellular oxygen concentrations (Sung, 2010).  
Considering the complex tumor microenvironment, SCO2 might support the viability of 
tumor cells by increasing energy efficacy in the presence of at least threshold levels of oxygen 
and thereby reduce glucose consumption. The less efficient glucose metabolism of SCO2-
lacking tumor cells could therefore be expected to result in increased necrosis formation. 
Indeed, the amount of necrosis was significantly increased in SCO2-depleted tumors 
compared to control tumors (Fig. 7). Similarly, inhibition of monocarboxylate transporter 1 
(MCT-1) has been shown to result in reduced oxidative phosphorylation and increased 
glucose consumption of tumor cells near blood vessels, leading to glucose depletion of tumor 
cells in the tumor core and subsequent extensive necrosis in these areas (Sonveaux et al., 
2008). 
In summary, this is the first report of SCO2 as a p53-dependent regulator of hypoxia 
sensitivity in glioma cells. Our results may have important implications for the understanding 
of the genetic basis of primary glioblastoma and may guide novel approaches towards tumor-
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selective therapies. Given the fundamental importance of p53 as a tumor-suppressor (Efeyan 
and Serrano, 2007; Kim et al., 2009) and the common loss of p53 in secondary glioblastomas 
(Ehrmann et al., 1995; Van Meir et al., 1994), the absence of p53 mutations in primary 
glioblastomas and the mutually exclusive occurrence of EGFR amplification and p53 
mutations have long puzzled researchers. The increasingly evident role of hypoxic stress as a 
key selective pressure for solid tumors (Anderson et al., 2006) has promoted research that 
aims to elucidate how cancer cells detect and process starvation signals and which pathways 
mediate adaptive responses that maintain viability (Jiang and Liu, 2008). Better understanding 
of these mechanisms may be exploited in several ways: (i) to establish molecular profiles that 
predict the susceptibility of cancer cells towards hypoxia. This will be of considerable 
importance, since common clinical interventions modulate tumor hypoxia. Examples include 
antiangiogenic therapies that increase tumor hypoxia, blood transfusions, erythropoietin 
application or oxygen delivery that decrease tumor hypoxia (Jansen et al., 2004; Puduvalli 
and Sawaya, 2000; Rieger et al., 2009) (ii) Interference with the adaptive responses towards 
starvation conditions by targeting key regulators of energy metabolism hold great promise as 
selective anti-tumor strategies. Specifically, SCO2 is a candidate molecule for this, because its 
suppression seems to be toxic only under hypoxic conditions. Co-therapy with strategies that 
target the availability or transport of glucose (Chan et al.) or the activity of glycolytic 
enzymes may further enhance the impact of suppression of SCO2 on tumor cells, because it 
will make them more dependent on cellular respiration. Strategies simultaneously targeting 
oxic and non-oxic metabolic pathways may therefore become an important component of 
novel antitumor therapies. 
 
Materials and methods 
Cell lines 
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LNT-229 carrying wild-type p53 activity (Lausanne, Switzerland) (Wischhusen et al., 2003) 
and LN-18 (endogenously mutant p53) cells were kindly provided from N. de Tribolet. T98G 
(endogenously mutant p53) were obtained from ATCC (Rockville, MD). LNT-229 cells 
expressing a short-hairpin construct for the gene suppression of p53 (LNT-229 p53sh) and 
puromycin-resistant control cells transfected with the empty vector (LNT-229 puro) 
(Wischhusen et al., 2003) and LNT-229 cells stably expressing the temperature-sensitive 
murine p53V135A possessing dominant-negative properties at 38.5°C (LNT-229 p53ts) and 
hygromycin-resistant control cells transfected with the empty vector (LNT-229 hygro) have 
been described (Naumann et al., 1998). Human HCT116 colon carcinoma cells carrying wild-
type p53 (p53+/+) and HCT116 cells with a targeted deletion of p53 (p53-/-) were provided by 
B. Vogelstein (Bunz et al., 1998). SCO2 short hairpin RNA in pLKO.1 was stably transduced 
into HCT116 p53+/+ cells (HCT116 p53+/+-SCO2 sh) and selected with puromycin for 10 
days. A scrambled shRNA in pLKO.1 was used as control (HCT116 p53+/+-scrambled sh). 
Gene expression was confirmed by RT-PCR. The glioma cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) (PAA, Coelbe, Germany) containing 10% fetal calf 
serum (FCS), 2 mM glutamine, 100 IU/mL penicillin and 100 mg/mL streptomycin. LNT-229 
hygro, LNT-229 p53ts cells and transfectants derived from those cells were cultivated at 
38.5°C. In experiments requiring defined glucose concentrations, glucose as required was 
added to DMEM glucose free medium (PAA). Cells were seeded at a density of 5.7x104 
cells/cm2 if not otherwise specified. 
 
Constructs 
Gene suppression of p53 was accomplished with the pSUPERpurop53shRNA vector 
(Wischhusen et al., 2003). The hygromycin control vector and the p53V135A construct were a 
gift from M. Clarke. The p53-luc reporter gene vector PathDetect p53 was purchased from 
Stratagene (Cedar Creek, TX), pRL-CMV Renilla vector was from Promega (Mannheim, 
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Germany). pcDNA3.1-SCO2 was generously provided by P. Hwang (Matoba et al., 2006). 
The control pcDNA3.1 vector was purchased from Invitrogen (Karlsruhe, Germany). Stable 
and transient transfections of plasmids were achieved using Metafectene pro (Biontex, 
Martinsried/Planegg, Germany) for LNT-229 or T98G cells. For stable knock down of human 
SCO2 expression, five different SCO2 shRNA (Sigma Aldrich, Taufkirchen, Germany) were 
each stably transduced into HCT116 p53+/+ cells via a pLKO.1-based lentiviral system. The 
envelope plasmid 8454 pCMV-VSV-G and packaging plasmid 8455 pCMV-dR8.2 dvpr were 
purchased from Addgene  (Cambridge, MA, USA). Protocol was adapted according to a 
previous report (Stewart et al., 2003). Experiments were carried out with the most effective 
SCO2 shRNA sequence (Sigma aldrich, TRCN0000236560, 5´ 
CCGGAGTTACCGCGTGTACTACAATCTCGAGATTGTAGTACACGCGGTAACTTTT
TTG-3´). A scrambled shRNA in pLKO.1 was used as control. For transient gene suppression 
of human SCO2, a predesigned small interfering RNA (siRNA) was employed (Sigma 
Aldrich, Taufkirchen, Germany). The following sequence targeting the coding region was 
used: 756-774: 5´-CAGUUACCGCGUGUACUAC [dT] [dT])-3´. A scrambled siRNA was 
used as control (Allstars negative siRNA, Qiagen, Hilden, Germany). Transient transfections 
with siRNA were achieved by HiPerfect (Qiagen) (3 µl Hiperfect : 20 nM siRNA per well in 
24-well plates, seeded at 100.000 cells per well).  
 
Induction of hypoxia 
Profound hypoxia (0.1% O2) was induced by incubating cells in Gas Pak pouches for 
anaerobic culture (Becton-Dickinson, Heidelberg, Germany) (Steinbach et al., 2003). 
Moderate hypoxia (1% O2) was induced in a Labotect incubator (Goettingen, Germany). 
Briefly, cells were seeded and allowed to attach in medium containing 10% FCS for 24 h. The 
medium was removed and the cells were incubated in serum-free DMEM adjusted to 2 mM 
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glucose under normoxia (21% O2), moderate (1% O2) or profound hypoxia (0.1% O2) for the 
indicated periods of time.  
 
Immunoblot analysis 
Cells were seeded in 6 well plates and exposed to serum-free medium containing 2 mM 
glucose in the presence of 21%, 1% or 0.1% O2 for 20 h as indicated. Thereafter, cells were 
washed with cold phosphate-buffered saline (PBS) and lysed in lysis buffer (50 mM Tris-HCl 
pH 8, 120 mM NaCl, 5 mM EDTA, 0.5% NP-40) containing protease inhibitors (Roche, 
Mannheim, Germany). Cellular lysates were prepared as described (Steinbach et al., 2003) 
and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Membranes were probed with antibodies to human p53 (sc-263, Santa Cruz, San Diego, CA), 
murine p53 (p53-Ab-4, Merck, Darmstadt, Germany), GAPDH (MAB374, Chemicon, 
Nuernberg, Germany), AMPKα (2531, Cell Signaling, Frankfurt am Main), p-AMPKα (Cell 
Signaling 2531, Germany), ACC (3662, Cell Signaling), p-ACC (3661, Cell Signaling), actin 
(SC1616, Santa Cruz) or p-4-EBP1 (9459, Cell Signaling). Secondary antibodies were 
purchased from Santa Cruz. The chemiluminescence solution used for detection was 
composed of 1 ml solution A (200 ml 0.1 M Tris-HCl pH 8.6, 50 mg Luminol), 100 µl 
solution B (11 mg p-hydroxycurmarinacid, 10 ml DMSO) and 0.3 µl H2O2 (30%). 
 
Luciferase assay 
Cells were seeded at 10000 cells per well into 96 well plates, cotransfected using Metafectene 
pro (Biontex) with the p53-luc reporter gene vector and pRL-CMV (Renilla) vector (Promega, 
Mannheim, Germany) at a ratio of 7.5 : 1, and exposed to 2 mM glucose and oxygen 
concentrations for 16 h. Experiments were conducted in triplicates. Activities of luciferase 
and firefly were determined using a luminometer (Mithras). Background was subtracted from 
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all values and the counts obtained from the measurement of firefly luciferase were normalized 
to Renilla luciferase (Dyer et al., 2000; Wischhusen et al., 2004). 
 
Cell death analysis 
Cells were seeded in 24 well plates at 50.000/cm2. After 24 h, medium was removed and cells 
were incubated in DMEM containing 2 mM glucose in the presence of 21%, 1% or 0.1% O2 
for 20 h. Thereafter, adherent and non-adherent cells were collected, washed in PBS, stained 
with 1 µg/ml PI, and analyzed by flow cytometry in a BD Canto II. PI-positive cells were 
regarded as dead cells, and the percentage of dead cells in relation to all analyzed cells was 
determined. Experiments were performed in triplicates and are presented as mean  standard 
deviation (SD). Selected results were replicated by LDH assay (Roche, Mannheim, Germany) 
according to manufacturer’s instructions. 
 
ROS analysis 
Cells were seeded in 24 well plates. After 24 h, medium was removed, and cells were 
incubated in DMEM containing 5 mM glucose in the presence of 21% or 1% O2 for 20 h. 
Cells were then washed twice with PBS, incubated 20 min, 37°C with 10 µM H2DCFDA 
(Invitrogen, Karlsruhe, Germany), washed with PBS and collected for flow cytometry 
analysis. DCF signal was analyzed by BD Canto II. Experiments were performed in triplicates 
and are presented as mean  standard deviation (SD). 
 
Measurement of glucose and lactate 
Cell-free supernatant was collected and glucose and lactate concentrations were measured 
using the biochemistry analyzer Hitachi 917. 
 
RNA extraction and quantitative reverse transcription-PCR (qRT-PCR) analysis. 
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Total RNA was extracted using Trizol and RNAeasy Kit (Invitrogen, Karlsruhe, Germany). 
First strand cDNA was synthesized using the Vilo cDNA synthesis kit (Invitrogen) for 10 min 
at 25°C and 2 h at 42°C. Subsequently, the enzyme was inactivated at 85°C for 10 min. To 
determine changes in gene expression, qRT-PCR was performed in the IQ5 real-time PCR 
detection system (Biorad, Muenchen, Germany) using Absolute Blue Q-PCR Mastermix with 
SybrGreen+Fluorescein (Thermo Fisher Scientific, Hamburg, Germany) and the following 
primer pairs: SCO2 fw 5´-CTTCACTCACTGCCCTGACA-3´, SCO2 bw 5´-
TGAGCAGGTAGATGGCAATG-3´, 18S fw 5´-CGGCTACCACATCCAAGGAA-3´, 18S 
bw 5´-GCTGGAATTACCGCGGCT-3´. Cycle threshold (Ct) values were normalized for 
amplification of the 18S ribosomal RNA and the data were analyzed using the Vandesompele 
method (28). 
 
Oxygen consumption 
250.000 cells were seeded in 3 cm diameter glass dishes. After 24 h, cells were treated with 
medium preincubated at the required temperature (37°C or 38.5°C), the lids were sealed using 
rubber gaskets and the dishes were tightly closed by two cramps. Oxygen concentration in the 
medium was measured using the ABL-80 FLEX Blood Gas Analyzer (Radiometer, Willich, 
Germany) before and after incubation for 48 h. Oxygen consumption was normalized for 
protein concentration. 
 
ATP assay 
Immediately after hypoxic incubation, the plates were placed on ice and the cells were 
pelleted by centrifugation and lysed in ATP releasing reagent (Sigma). The ATP 
concentration was determined by luciferase assay with the CLS II kit (Boehringer, Mannheim, 
Germany) (Steinbach et al., 2003). 
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Anchorage independent growth (Soft agar colony assay) 
Cells were suspended in 0.35% agar medium (DMEM containing 5.5 mM glucose, 10% FCS, 
2 mM GlutaMAX™-I Supplement (Invitrogen)) at a concentration of 5 × 103 cells per 6-cm 
dish, and then plated on a 0.5% agar base layer (also containing 5.5 mM glucose, 10% FCS 
and 2 mM GlutaMAX™-I Supplement). GlutaMAX™ contains L-alanyl-L-glutamine, a 
stabilized form of L-glutamine, preventing degradation and ammonia build-up during long-
term cultures. Cells were then incubated in a humidified atmosphere (5% CO2) at 37°C. 24 h 
after seeding, 2 ml of medium were added on the top agar and cells were incubated at 3% O2 
for at least 4 weeks. Colonies were stained by 0.0025% crystal violet for 4 h and counted 
thereafter. 
 
In vivo assays 
4 x 106 HCT116 p53+/+ and p53-/- cells and 2 x 106 p53+/+ scrambled sh or -SCO2 sh cells 
were injected subcutaneously (s. c.) in both lower back sides of 6-week-old female athymic 
nude mice (Foxn1nu, Harlan, Indianapolis, IN). 10 mice (corresponding to 20 tumors) were 
used for HCT116 p53+/+ /p53-/- cells, 6 mice were used (12 tumors) for p53+/+ scrambled sh / 
SCO2 sh cells. A smaller amount of cells in the scrambled/SCO2 sh model were used to 
observe tumors for a longer period of time. The size of the transplanted tumors was measured 
three times per week by means of a caliper. Tumor volume was calculated by use of the 
formula π/6*length*width2 (Kopper and Steel, 1975). Animals were sacrificed before the 
average of tumor volumes reached 1.500 mm3. Experiments were conducted according to the 
guidelines for ethical use of animals of the Helsinki declaration under an approved protocol. 
The doubling times of the subcutaneous tumors was calculated by dividing the natural 
logarithm of 2 by the exponent of an exponential growth curve calculated for each tumor. 
Thereafter, doubling times between the groups were compared by t-test. 
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Necrosis fraction determination 
Shortly after surgical removal, tumors were fixed and embedded in 4% paraffin. Blocks were 
cut with a microtome (3 µm thickness), placed on Super-Frost Plus slides (Microm 
International, Walldorf, Germany) and stained with haematoxylin and eosin (H&E). Slices 
were scanned and the extent of necrosis in relation to total tumor area was determined using 
ImageJ software (Research Services Branch, National Institute of Mental Health, Bethesda). 
To analyze tumors of comparable size, tumors of less than 500 mm3 were excluded from the 
analysis. 
 
Chemicals 
All chemicals not otherwise specified below were from Sigma Aldrich (Deisenhofen, 
Germany), Invitrogen (Karlsruhe, Germany) or Roth (Karlsruhe, Germany). 
 
Statistics 
Values were compared by two-tailed student´s t-test (Excel, Microsoft, Seattle, WA), and p-
values of p < 0.05 and p < 0.01 were considered significant and highly significant. 
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Figure Legends 
Fig. 1: Antagonizing p53 enhances hypoxia-induced cell death. Three different model 
systems for the suppression of p53 function were employed. LNT-229 p53sh cells or puro 
control cells (upper panel), LNT-229 p53ts cells carrying the temperature-sensitive dominant-
negative mutant p53V135A or hygro control cells (middle panel), and the HCT116 system with 
the p53 -/- subline or the p53+/+ parental cells (lower panel). (A) Tumor cells were incubated at 
21%, 1% or 0.1% O2, and the expression of endogenous human p53 (p53sc263-antibody) or 
murine p53 (Ab4-antibody) for the detection of the murine p53ts transgene were analyzed by 
Western blot. GAPDH expression was employed as loading control. (B) p53 transactivation 
activity under the denoted conditions was determined by a luciferase assay (mean  SD). (C) 
Cells were treated as in (A), and cell death was analyzed by PI-FACS (left panel). Scatter 
plots are of representative experiments showing forward scatter vs. PI uptake. Cells above the 
horizontal gates shown in red were defined as dead cells (right panel). Relative percentages of 
dead cells under these conditions as determined in triplicates are shown (mean  SD). * p< 
0.05, ** p<0.01. 
 
Fig. 2: p53 is a regulator of glucose consumption in tumor cells. LNT-229 puro and LNT-
229 p53 sh cells (A-B) or HCT116 p53+/+/p53-/- cells (C-D) were treated as denoted for the 
indicated periods of time, and glucose consumption (A, C) and lactate production (B, D) were 
assessed. A representative experiment of 3 independent experiments is shown.  
 
Fig. 3: Inhibiting p53 function represses cellular respiration and expression of SCO2. 
LNT-229 puro/p53sh (left panel), LNT-229 hygro/p53ts (middle panel) or HCT116 
p53+/+/p53-/- cells (right panel) were analyzed for (A) SCO2 expression by quantitative RT-
PCR (error bars represent standard deviation measured in three samples and standardized to 
  22
18S, * p< 0.05, ** p<0.01) and (B) oxygen consumption. For B, a representative experiment 
out of 3 independent experiments with similar results is shown.  
 
Fig. 4: SCO2 is a p53 effector that maintains respiration and reduces sensitivity towards 
hypoxic induced cell death. LNT-229, T98G (p53 mutant) or LNT-229 puro/p53sh cells 
were stably transfected with pcDNA3-SCO2 (SCO2) or a control plasmid (neo). Further, 
LNT-229 cells were transiently transfected with a siRNA targeting SCO2 (SCO2si) or a 
scrambled siRNA (scr si). In these cell lines, (A) expression of SCO2 (error bars represent 
standard deviation measured in three samples and standardized to 18S, * p< 0.05, ** p<0.01), 
(B) oxygen consumption and (C) hypoxia-induced cell death (mean  SD) were analyzed. * 
p< 0.05, ** p<0.01. For B, a representative experiment out of 3 independent experiments with 
similar results is shown. 
 
Fig. 5: A functional respiratory chain is required for the SCO2-mediated protection. (A) 
LNT-229 p53sh cells ectopically expressing SCO2 (SCO2) or empty pcdna3 vector-
transfected p53sh cells (neo) were exposed to rotenone (100 nM) or vehicle for 24 h, and 
oxygen consumption was determined (A). Additionally, cell death induced by moderate 
hypoxia (1%) in the absence or presence of rotenone was analyzed in these cells (mean  SD). 
* p< 0.05, ** p<0.01 (B). T98G cells ectopically expressing SCO2 (SCO2) or empty pcdna3 
vector-transfected T98G cells (neo) and LNT-229 hygro/p53ts cells stably transfected with 
pcDNA3-SCO2 (SCO2) or a control plasmid (neo) were exposed to serum-free media 
containing 2 or 25 mM glucose under moderate hypoxia (1% O2) for 24 h, and cell death was 
assayed by PI-FACS (mean  SD), * p< 0.05, ** p<0.01 (C). LNT-229 hygro and LNT-229 
p53ts cells were exposed to serum-free media containing 2 mM glucose with or without 10 
mM methyl-pyruvate under moderate hypoxia (1% O2) for 24 h, and cell death was assayed 
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by PI-FACS (mean SD). * p< 0.05, ** p<0.01 (D). Here, a representative experiment out of 
3 independent experiments with similar results is shown.  
 
Fig.6: Suppression of SCO2 does not impair clonogenicity in vitro 
HCT116 p53+/+ and p53-/- cells (A) and HCT116 p53+/+ scrambled sh/SCO2 sh cells (B) were 
seeded into a 3D agar matrix on top of a base agar layer in presence of 5.5 mM glucose and 
3% O2. After 4-6 weeks of incubation, colonies were stained by 0.0025% crystal violet and 
the number of colonies formed in each well was counted. The bars represent the average ± SD 
of three wells counted for each group. The results were confirmed in at least 3 independent 
experiments ** p < 0.001.  
 
Fig. 7: Depletion of SCO2 promotes necrosis formation. 
(A) HCT116 p53+/+ and p53-/-cells, and (B) HCT116 p53+/+ scrambled sh/SCO2 sh cells were 
injected s.c. in the lower back side of 6-week-old female athymic nude foxn1 nu mice. The 
size of the transplanted tumors was measured three times per week with a caliper. Data are 
mean ± SEM, n.s.: no significant difference in doubling times. (C) After surgical removal, 
HCT116 p53+/+ scrambled sh/SCO2 sh tumors were fixed and stained with H&E. (upper 
panel). Necrosis fraction of tumors was determined and compared by t-test (n=7 for 
scrambled sh and n=10 for SCO2 sh tumors, ** p < 0.001). (lower panel). Representative 
slices of scrambled sh and SCO2 sh tumors are shown.  
 
Fig. 8: Schematic drawing showing the regulation of hypoxia-induced cell death through 
p53-dependent expression of SCO2. (A) In the presence of wild-type p53, starvation signals 
induce p53 via the AMPK sensor system. P53 suppresses glycolysis and induces SCO2, 
which promotes oxidative phosphorylation in the mitochondria. Under the conditions of the 
tumor microenvironment characterized by hypoxia and low glucose availability, increased 
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efficacy of ATP production in the mitochondria serves to maintain energy homeostasis and 
viability. Furthermore, expression of SCO2 limits ROS levels. (B) Inactivation of p53 or 
suppression of SCO2 deregulates glycolysis and impairs mitochondrial respiration leading to 
increased glucose consumption, while the amount of ATP generated per Mol glucose is 
decreased. Under starvation conditions, these metabolic alterations induce rapid energy 
depletion and subsequent cell death. Reduced expression of SCO2 results in increased 
intracellular ROS levels which may further contribute to cell death.  
 
Supplementary Figures: 
Suppl. Fig. 1: SCO2 expression leads to higher ATP levels under moderate hypoxia. 
LNT-229 hygro or p53ts cells stably transfected with pcDNA3-SCO2 (SCO2) or a control 
plasmid (neo) were exposed to serum-free media containing 2 mM glucose under moderate 
hypoxia (1% O2) for 16 h and ATP concentrations were measured as described (mean  SD). 
* p< 0.05, ** p<0.01. A representative experiment out of 3 independent experiments with 
similar results is shown. 
 
Suppl. Fig. 2: SCO2 expression has no impact on phosphorylation of AMPKα or ACC 
under moderate hypoxia. T98G cells ectopically expressing SCO2 (SCO2) or empty pcdna3 
vector-transfected T98G cells (neo) were exposed to serum-free media containing 2 mM 
glucose under moderate hypoxia, and expression of ACC, phosphorylated ACC (p-ACC), 
AMPKα, phosphorylated AMPKα (p-AMPKα) and phosphorylated 4EBP1 (p-4EBP1) were 
analyzed by Western blot. The glycolysis inhibitor 2-deoxyglucose (2-DG) (5 mM) was 
employed as a positive control, and actin expression was used as loading control. A 
representative experiment out of 2 independent experiments with similar results is shown. 
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Suppl. Fig. 3: SCO2 suppresses intracellular ROS concentrations in glioma cells. LNT-
229 and T98G cells ectopically expressing SCO2 (SCO2) or empty pcdna3 vector-transfected 
LNT-229 and T98G cells (neo) were exposed to serum-free media containing 5 mM glucose 
under normoxia or moderate hypoxia (1%) for 24 h, and ROS levels were determined. * p < 
0.05. A representative experiment out of 3 independent experiments with similar results is 
shown. 
 
References 
 
Anderson AR, Weaver AM, Cummings  PT, Quaranta V  (2006).  Tumor morphology  and phenotypic 
evolution driven by selective pressure from the microenvironment. Cell 127: 905‐15. 
 
Barnes K, Ingram JC, Porras OH, Barros LF, Hudson ER, Fryer LG et al (2002). Activation of GLUT1 by 
metabolic and osmotic stress: potential  involvement of AMP‐activated protein kinase (AMPK). J Cell 
Sci 115: 2433‐42. 
 
Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R et al (2006). TIGAR, a p53‐inducible 
regulator of glycolysis and apoptosis. Cell 126: 107‐20. 
 
Bhonde MR, Hanski ML, Notter M, Gillissen BF, Daniel PT, Zeitz M et al (2006). Equivalent effect of 
DNA  damage‐induced  apoptotic  cell  death  or  long‐term  cell  cycle  arrest  on  colon  carcinoma  cell 
proliferation and tumour growth. Oncogene 25: 165‐75. 
 
Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al (1998). Requirement for p53 and 
p21 to sustain G2 arrest after DNA damage. Science 282: 1497‐501. 
 
Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F et al (2007). Systemic treatment 
with the antidiabetic drug metformin selectively impairs p53‐deficient tumor cell growth. Cancer Res 
67: 6745‐52. 
 
Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A et al Targeting GLUT1 and the Warburg 
effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 3: 94ra70. 
 
Choe  G,  Horvath  S,  Cloughesy  TF,  Crosby  K,  Seligson  D,  Palotie  A  et  al  (2003).  Analysis  of  the 
phosphatidylinositol  3'‐kinase  signaling  pathway  in  glioblastoma  patients  in  vivo.  Cancer  Res  63: 
2742‐6. 
 
Corcoran CA, Huang Y, Sheikh MS (2006). The regulation of energy generating metabolic pathways by 
p53. Cancer Biol Ther 5: 1610‐3. 
 
Curi  R, Newsholme  P, Newsholme  EA  (1988). Metabolism  of  pyruvate  by  isolated  rat mesenteric 
lymphocytes, lymphocyte mitochondria and isolated mouse macrophages. Biochem J 250: 383‐8. 
 
  26
DeBerardinis  RJ,  Lum  JJ, Hatzivassiliou G,  Thompson  CB  (2008).  The  biology  of  cancer: metabolic 
reprogramming fuels cell growth and proliferation. Cell Metab 7: 11‐20. 
 
Dyer  BW,  Ferrer  FA,  Klinedinst DK,  Rodriguez  R  (2000). A  noncommercial  dual  luciferase  enzyme 
assay system for reporter gene analysis. Anal Biochem 282: 158‐61. 
 
Efeyan A, Serrano M (2007). p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 
6: 1006‐10. 
 
Ehrmann  J,  Kolar  Z,  Kala  M,  Vojtesek  B,  Komenda  S  (1995).  Expression  of  p53  in  glioblastoma 
multiforme cells: relationship to survival, proliferation and glycosylation. Cesk Patol 31: 87‐91. 
 
Fults  D,  Brockmeyer  D,  Tullous MW,  Pedone  CA,  Cawthon  RM  (1992).  p53 mutation  and  loss  of 
heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 52: 
674‐9. 
 
Gatenby RA, Gillies RJ (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891‐9. 
 
Gottlieb E (2009). Cancer: The fat and the furious. Nature 461: 44‐5. 
 
Guppy M, Greiner E, Brand K (1993). The role of the Crabtree effect and an endogenous fuel  in the 
energy metabolism of resting and proliferating thymocytes. Eur J Biochem 212: 95‐9. 
 
Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell 100: 57‐70. 
 
Jansen M, de Witt Hamer PC, Witmer AN, Troost D, van Noorden CJ (2004). Current perspectives on 
antiangiogenesis strategies  in the treatment of malignant gliomas. Brain Res Brain Res Rev 45: 143‐
63. 
 
Jiang BH, Liu LZ (2008). PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 
1784: 150‐8. 
 
Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y et al (2005). AMP‐activated protein kinase induces a 
p53‐dependent metabolic checkpoint. Mol Cell 18: 283‐93. 
 
Kim  E,  Giese  A,  Deppert  W  (2009).  Wild‐type  p53  in  cancer  cells:  when  a  guardian  turns  into  a 
blackguard. Biochem Pharmacol 77: 11‐20. 
 
Kondoh  H,  Lleonart  ME,  Gil  J,  Wang  J,  Degan  P,  Peters  G  et  al  (2005).  Glycolytic  enzymes  can 
modulate cellular life span. Cancer Res 65: 177‐85. 
 
Kopper  L,  Steel  GG  (1975).  The  therapeutic  response  of  three  human  tumor  lines  maintained  in 
immune‐suppressed mice. Cancer Res 35: 2704‐13. 
 
Leary SC, Kaufman BA, Pellecchia G, Guercin GH, Mattman A, Jaksch M et al (2004). Human SCO1 and 
SCO2 have independent, cooperative functions in copper delivery to cytochrome c oxidase. Hum Mol 
Genet 13: 1839‐48. 
 
Leary SC, Sasarman F, Nishimura T, Shoubridge EA (2009). Human SCO2 is required for the synthesis 
of CO II and as a thiol‐disulphide oxidoreductase for SCO1. Hum Mol Genet. 
 
  27
Liu  T,  Laurell  C,  Selivanova  G,  Lundeberg  J,  Nilsson  P,  Wiman  KG  (2007).  Hypoxia  induces  p53‐
dependent transactivation and Fas/CD95‐dependent apoptosis. Cell Death Differ 14: 411‐21. 
 
Ma W,  Sung HJ,  Park  JY, Matoba  S, Hwang  PM  (2007).  A  pivotal  role  for  p53:  balancing  aerobic 
respiration and glycolysis. J Bioenerg Biomembr 39: 243‐6. 
 
Matoba  S,  Kang  JG,  Patino  WD,  Wragg  A,  Boehm  M,  Gavrilova  O  et  al  (2006).  p53  regulates 
mitochondrial respiration. Science 312: 1650‐3. 
 
Miyamoto S, Murphy AN, Brown JH (2008). Akt mediates mitochondrial protection in cardiomyocytes 
through phosphorylation of mitochondrial hexokinase‐II. Cell Death Differ 15: 521‐9. 
 
Moreno‐Sanchez R, Rodriguez‐Enriquez S, Marin‐Hernandez A, Saavedra E (2007). Energy metabolism 
in tumor cells. Febs J 274: 1393‐418. 
 
Naumann U, Durka S, Weller M (1998). Dexamethasone‐mediated protection from drug cytotoxicity: 
association with p21WAF1/CIP1 protein accumulation? Oncogene 17: 1567‐75. 
 
Ohgaki H, Kleihues P (2007). Genetic pathways to primary and secondary glioblastoma. Am J Pathol 
170: 1445‐53. 
 
Puduvalli VK, Sawaya R (2000). Antiangiogenesis ‐‐ therapeutic strategies and clinical implications for 
brain tumors. J Neurooncol 50: 189‐200. 
 
Rieger J, Bahr O, Muller K, Franz K, Steinbach J, Hattingen E (2009). Bevacizumab‐induced diffusion‐
restricted lesions in malignant glioma patients. J Neurooncol. 
 
Ryan  JJ, Danish  R, Gottlieb  CA,  Clarke MF  (1993).  Cell  cycle  analysis  of  p53‐induced  cell  death  in 
murine erythroleukemia cells. Mol Cell Biol 13: 711‐9. 
 
Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN et al (2008). Targeting lactate‐
fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118: 3930‐42. 
 
Steinbach JP, Wolburg H, Klumpp A, Probst H, Weller M (2003). Hypoxia‐induced cell death in human 
malignant  glioma  cells:  energy  deprivation  promotes  decoupling  of  mitochondrial  cytochrome  c 
release from caspase processing and necrotic cell death. Cell Death Differ 10: 823‐32. 
 
Stewart  SA, Dykxhoorn DM,  Palliser D, Mizuno H,  Yu  EY, An DS  et  al  (2003).  Lentivirus‐delivered 
stable gene silencing by RNAi in primary cells. Rna 9: 493‐501. 
 
Sung HJ  (2010). Mitochondrial respiration protects against oxygen‐associated DNA damage. Nature 
communications 1: 1‐8. 
 
Tohma Y, Gratas C, Van Meir EG, Desbaillets I, Tenan M, Tachibana O et al (1998). Necrogenesis and 
Fas/APO‐1  (CD95) expression  in primary  (de novo) and secondary glioblastomas. J Neuropathol Exp 
Neurol 57: 239‐45. 
 
Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE et al (1994). Analysis of the p53 gene 
and its expression in human glioblastoma cells. Cancer Res 54: 649‐52. 
 
Vogelstein B, Lane D, Levine AJ (2000). Surfing the p53 network. Nature 408: 307‐10. 
 
  28
Warburg O (1956a). On respiratory impairment in cancer cells. Science 124: 269‐70. 
 
Warburg O (1956b). On the origin of cancer cells. Science 123: 309‐14. 
 
Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H  (1996). Overexpression of the 
EGF  receptor and p53 mutations are mutually exclusive  in  the evolution of primary and secondary 
glioblastomas. Brain Pathol 6: 217‐23; discussion 23‐4. 
 
Wischhusen J, Melino G, Weller M (2004). p53 and its family members ‐‐ reporter genes may not see 
the difference. Cell Death Differ 11: 1150‐2. 
 
Wischhusen  J,  Naumann  U,  Ohgaki  H,  Rastinejad  F,  Weller  M  (2003).  CP‐31398,  a  novel  p53‐
stabilizing  agent,  induces  p53‐dependent  and  p53‐independent  glioma  cell  death.  Oncogene  22: 
8233‐45. 
 
Yoon CH, Lee ES, Lim DS, Bae YS  (2009). PKR, a p53  target gene, plays a crucial  role  in  the  tumor‐
suppressor function of p53. Proc Natl Acad Sci U S A 106: 7852‐7. 
 
Zhao Y, Chen XQ, Du  JZ  (2009). Cellular  adaptation  to hypoxia  and p53  transcription  regulation.  J 
Zhejiang Univ Sci B 10: 404‐10. 
 
 
 
